8-K: Bio-Rad Reports Q3 2025 Results, Operating Margin Exceeds Expectations

Bio-Rad Laboratories announced third-quarter 2025 financial results, reporting modest revenue growth and a better-than-expected operating margin despite market challenges.

Summary

• Total net sales for Q3 2025 were $653.0 million, a 0.5% increase compared to $649.7 million in Q3 2024.
• On a currency-neutral basis, quarterly sales decreased by 1.7% year-over-year.
• Life Science Group net sales increased by 0.3% to $261.8 million, but decreased by 1.5% on a currency-neutral basis due to constrained academic research and biotech funding.
• Clinical Diagnostics Group net sales increased by 0.6% to $391.2 million, but decreased by 1.8% on a currency-neutral basis, primarily due to lower reimbursement rates for diabetes testing in China.
• GAAP net loss was $(341.9) million, or $(12.70) per diluted share, primarily due to a change in the fair market value of the investment in Sartorius AG.
• Non-GAAP net income was $60.8 million, or $2.26 per diluted share, compared to $56.3 million, or $2.02 per diluted share, in Q3 2024.
• The company maintained its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of approximately 0% to 1.0% and a non-GAAP operating margin of approximately 12.0% to 13.0%.

Sentiment

Score: 6

Explanation: While GAAP net income was a significant loss due to a non-operating fair value adjustment, the underlying non-GAAP operating performance was solid, with better-than-expected operating margins and growth in non-GAAP net income and EPS. The company also maintained its full-year outlook despite market headwinds, indicating stability.

Positives

• Non-GAAP operating margin was better-than-expected, reflecting disciplined cost management.
• Non-GAAP net income increased to $60.8 million in Q3 2025 from $56.3 million in Q3 2024, an 8.0% increase.
• Non-GAAP diluted earnings per share rose to $2.26 in Q3 2025 from $2.02 in Q3 2024.
• Free cash flow for the nine months ended September 30, 2025, increased to $255.5 million from $208.3 million in the same period of 2024.
• The company successfully completed the acquisition of Stilla Technologies on June 30, 2025.

Negatives

• GAAP net income resulted in a significant loss of $(341.9) million, primarily driven by a negative change in the fair market value of the investment in Sartorius AG.
• Currency-neutral total net sales decreased by 1.7% year-over-year, indicating underlying sales contraction.
• Life Science Group's currency-neutral sales decreased by 1.5% due to constrained academic research and biotech funding.
• Clinical Diagnostics Group's currency-neutral sales decreased by 1.8% due to lower reimbursement rates for diabetes testing in China.
• GAAP gross margin declined to 52.6% in Q3 2025 from 54.8% in Q3 2024.

Risks

• Risks relating to international operations, including global economic and geopolitical conditions.
• Potential impact of tariffs or other trade barriers.
• Reductions in government funding or capital spending by customers.
• Uncertain pace of recovery in the biopharma sector.
• International legal and regulatory risks.
• Challenges in developing and marketing new or improved products.
• Ability to compete effectively in the market.
• Foreign currency exchange fluctuations impacting financial results.
• Difficulties in successfully integrating acquired companies, products, or technologies.
• Supply chain issues and disruptions.
• Product quality and liability issues.
• Changes in the healthcare industry landscape.
• Impact of natural disasters and other catastrophic events beyond control.

Future Outlook

Bio-Rad Laboratories is maintaining its financial outlook for the full year 2025. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 0% to 1.0% and a non-GAAP operating margin of approximately 12.0% to 13.0%. Additionally, the company forecasts a non-GAAP gross margin of 53.5% to 54.5% and free cash flow of $310 million to $330 million for the full year.

Management Comments

• "During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products."
• "Despite ongoing challenges in academic research and biotech funding, and the resulting reduced demand for instruments, our teams delivered solid results in Q3."
• "Our ongoing focus on disciplined cost management contributed to a better-than-expected operating margin."

Industry Context

The company's performance reflects broader industry trends, including constrained academic research and biotech funding, which impacted the Life Science Group's instrument demand. The Clinical Diagnostics Group faced challenges from lower reimbursement rates for diabetes testing in China, highlighting regional regulatory and market pressures. Despite these headwinds, the company's focus on cost management allowed it to achieve a better-than-expected operating margin, suggesting resilience in a dynamic global environment.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The significant GAAP net loss due to the Sartorius AG investment fair value change could concern shareholders, but the positive non-GAAP performance and maintained outlook may reassure them about core business health.
• Employees: The focus on disciplined cost management could imply ongoing scrutiny of operational expenses, potentially impacting employees through efficiency initiatives.
• Customers: Continued challenges in academic research and biotech funding, along with lower reimbursement rates in China, suggest a difficult market environment for customers in these segments, potentially affecting future sales.
• Creditors: The stable long-term debt and positive free cash flow generation indicate a healthy financial position to meet obligations.

Next Steps

• Management will discuss the company's third quarter 2025 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on October 29, 2025.
• A live webcast of the conference call and supplemental earnings presentation will be available on the company's investor relations website.

Key Dates

Recommendation

The filing presents a mixed picture. While the GAAP net loss is substantial, it's primarily driven by a non-cash, non-operating fair value adjustment of the Sartorius AG investment, which should be viewed separately from core operations. The non-GAAP results show resilience with better-than-expected operating margins and growth in non-GAAP net income and EPS, indicating effective cost management. However, currency-neutral revenue declines in both segments due to external market challenges (academic funding, biotech funding, China reimbursement rates) suggest ongoing headwinds. The maintained full-year outlook implies management is navigating these challenges effectively, but significant growth catalysts are not immediately apparent. Given the external pressures balanced by internal operational strength, a 'hold' recommendation is appropriate for investors to monitor how the company navigates these market dynamics and if revenue growth can re-accelerate.

Keywords

Bio-Rad Laboratories, BIO, Clinical Diagnostics, Life Science Research, Financial Results, Q3 2025, Earnings, SEC Filing, Biotech Funding, Academic Research, Operating Margin, Revenue, Sartorius AG, Stilla Technologies